Sidewinder Therapeutics Raises $137M Series B to Advance Next-Generation Bispecific ADCs for Cancer Treatment
核心洞察
Sidewinder Therapeutics (搜索) secured $137 million in Series B financing co-led by Frazier Life Sciences (搜索) and Novartis Venture Fund (搜索) to advance next-generation bispecific antibody-drug conjugates (搜索).
The company is developing bispecific ADCs (搜索) that target receptor co-complexes highly expressed on solid tumors, combining an oncogenic driver receptor (搜索) with an internalizing receptor (搜索) for enhanced precision.
Sidewinder plans to focus on cancer (搜索) indications with limited treatment options affecting large populations, including colorectal tumors, squamous cell carcinomas (搜索) in lung and head and neck cancers (搜索).
Sidewinder Therapeutics (搜索) has closed an oversubscribed $137 million Series B financing round to advance its next-generation bispecific antibody-drug conjugates (搜索) (ADCs) for cancer (搜索) treatment. The financing was co-led by Frazier Life Sciences (搜索) and Novartis Venture Fund (搜索), with participation from OrbiMed (搜索) and new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management and Alexandria Venture Investments.
Advancing Precision ADC Technology
Sidewinder is developing bispecific ADCs (搜索) designed to target receptor co-complexes that are highly expressed on certain solid tumors. The company's approach focuses on tumor-specific co-complexes consisting of an oncogenic driver receptor (搜索) and an internalizing receptor (搜索). This dual-targeting strategy is intended to enhance both tumor cell specificity and internalization, improving drug delivery to cancer (搜索) cells while avoiding normal cells.
"The ADC field is at an inflection point driven by technological breakthroughs enabling next-generation bispecific ADCs (搜索), and Sidewinder is eager to lead this wave of innovation and advance promising therapies for patients with cancer (搜索)," said Eric Murphy, Ph.D., Co-Founder and CEO of Sidewinder Therapeutics (搜索).
The company's pipeline features bispecific antibodies engineered from internally discovered antibody sequences and finely tuned to target these tumor-specific co-complexes. Sidewinder believes focusing on these protein combinations could lead to a more targeted and effective attack on tumors compared to traditional ADC approaches.
Targeting High-Need Cancer Indications
Sidewinder's programs are designed to address oncology indications that have limited treatment options and affect substantial patient populations. The company plans to focus on squamous cell carcinomas (搜索) in lung and head and neck cancers (搜索) as well as gastrointestinal cancers (搜索) including colorectal cancer (搜索). These cancer (搜索) types represent areas with significant unmet medical needs despite affecting large patient populations.
The company expects to advance its lead program into clinical development in 2027, though specific targets for the lead program were not disclosed.
Strategic Partnerships and Funding Milestones
Founded in 2023 with Series A backing from OrbiMed (搜索), Sidewinder has now raised a total of $162 million including the latest financing. The company recently partnered with Lonza's Synaffix subsidiary to gain access to ADC technology that has been licensed to several other firms.
Concurrent with the Series B financing, Daniel Estes, Ph.D., from Frazier Life Sciences (搜索), Michal Silverberg from Novartis Venture Fund (搜索), Josh Richardson, M.D., from Life Sciences at Goldman Sachs Alternatives and John Hamer, Ph.D., from DCVC Bio were named to the Board of Directors.
Market Context and Innovation Wave
Sidewinder is part of a broader wave of companies working to improve upon ADC technology. While ADCs have emerged as a more precise way to kill cancer (搜索) by chemically linking toxic payloads to targeting molecules, their reach remains limited, spurring investment in developers working on new methods to advance the field further.
The company's bispecific approach represents an attempt to address current limitations by targeting protein combinations rather than single targets, potentially offering improved precision and efficacy in cancer (搜索) treatment.